Mayo Clinic opens a varenicline trial aimed at smoking cessation in pancreatitis
Smoking remains one of the most consequential modifiable exposures in pancreatitis, and Mayo Clinic is moving directly at that risk with a phase 4 study of varenicline in adults with acute, recurrent acute, or chronic pancreatitis. The single-center, open-label trial is designed to test whether a standard 12-week course can help participants stop smoking cigarettes completely, with quit status confirmed by exhaled carbon monoxide.
The study is not built around an abstract prevention concept. It is anchored to a bedside problem that clinicians face constantly: patients with pancreatitis who continue to smoke despite knowing the stakes. Tobacco exposure can compound pancreatic injury, reinforce inflammation, and make long-term disease control harder to achieve. In that setting, a cessation therapy that is already familiar to clinicians could be especially useful if it proves feasible in this population.
A 12-week oral regimen with standard titration
All enrolled participants will receive oral varenicline for 12 weeks. Dosing begins with 0.5 mg once daily on days 1 through 3, rises to 0.5 mg twice daily on days 4 through 7, and then continues at 1 mg twice daily from day 8 through the end of treatment.
The study uses a single-group assignment with no masking. Every participant receives the same intervention, which keeps the design straightforward and makes the signal easier to interpret in a small early-phase behavioral study. Investigators will not be comparing varenicline against placebo or another cessation medication here; instead, they will ask whether the drug can be delivered safely, whether participants stay engaged, and whether quitting rates justify a larger next-step trial.
A single-sentence reality frames the whole protocol: smoking cessation is being treated here as a pancreatitis intervention, not just a lifestyle goal.
Why varenicline is being tested in this population
Varenicline is a commonly used smoking cessation medication, and its pharmacology makes it a logical choice for patients who need more than counseling alone. By partially stimulating nicotinic receptors while blocking the reinforcing effects of nicotine, it can blunt withdrawal and reduce the reward associated with smoking. In a pancreatitis population, where pain, stress, and entrenched smoking habits can all complicate cessation, that mechanism offers a practical advantage.
The trial’s rationale also fits with the disease biology. Pancreatitis—whether acute, recurrent acute, or chronic—sits on a spectrum of pancreatic injury and persistent inflammation. Continued cigarette smoking can aggravate that trajectory and may make recovery harder. A medication that helps patients stop smoking could therefore influence more than nicotine dependence; it may remove one of the exposures that perpetuates pancreatic damage.
Eligibility criteria show how carefully the population has been defined. Adults 18 years and older are eligible if they have acute pancreatitis, recurrent acute pancreatitis, or chronic pancreatitis as defined by the American Pancreatic Association, smoke cigarettes daily or on most days, average at least five cigarettes per day over the past 30 days, and explicitly want to quit within 30 days. Participants must be able to take oral medication, comply with follow-up, and provide informed consent.
Safety boundaries are narrow by design
The exclusion criteria are clinically important because they mark the limits of where varenicline can be used safely in this protocol. People with known hypersensitivity to varenicline are excluded, as are those with active seizure disorder or another medical condition judged by the investigator to make the drug unsafe. The trial also excludes patients with creatinine clearance below 30 mL/minute, untreated psychotic disorder, acute manic episode, or inability to consent.
Those exclusions matter because varenicline is being studied in a medically complex group rather than in otherwise healthy smokers. Pancreatitis patients may carry substantial comorbidity, and the protocol’s guardrails are designed to reduce avoidable risk while still testing the treatment in the population most likely to use it.
Quit rates, reduction in smoking, and retention will define success
The primary endpoint is smoking cessation at 12 weeks, measured as complete quitting by the end of treatment and confirmed with exhaled carbon monoxide. That objective verification is essential; self-report alone would be too fragile in a cessation trial, especially one focused on a disease population in which smoking history is closely tied to prognosis.
Secondary outcomes extend the picture beyond a binary quit-or-not result. Investigators will measure reduction in smoking from baseline to 12 weeks, retention through 24 weeks, and treatment acceptability using the Treatment Evaluation Inventory Short Form. Scores above 27 on that instrument indicate at least moderate acceptability. Those endpoints should help clarify whether the medication is merely tolerable or actually workable in real clinical follow-up.
The retention measure is especially revealing. A cessation intervention can fail in a subtle way long before the final quit rate is known, simply because patients disengage from visits or stop taking the medicine. In a single-center study, every completed carbon monoxide test and follow-up assessment carries practical weight.
Enrollment is small, but the clinical question is precise
The estimated enrollment is 45 participants, with the study start projected for 2026-11-13. Primary completion is estimated for 2028-11-01, and full study completion for 2029-11-01. Mayo Clinic is sponsoring the trial, and the listed principal investigator is Samuel Han.
This is a modest study in size, but the question is concrete: can a standard varenicline regimen help smokers with pancreatitis quit, and will they accept the treatment well enough for it to be used in routine care? A prior publication from the same investigative group examined smoking cessation in a chronic pancreatitis population, and another recent paper assessed direct and passive smoking across the pancreatitis spectrum. Those publications make the current trial feel like the next logical step, moving from describing the smoking burden to testing an actionable intervention.
The open-label design will not answer every question. Without a comparator arm, the trial cannot separate medication effect from counseling, motivation, or regression to the mean. It also will not resolve whether varenicline changes pancreatitis outcomes themselves. What it can do is establish whether the treatment is feasible in a population where smoking cessation has unusually high clinical value and where even partial success could reduce future pancreatic injury.